Treatment of traumatic brain injury with vepoloxamer
维泊洛沙姆治疗颅脑损伤
基本信息
- 批准号:9814366
- 负责人:
- 金额:$ 32.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-06-01 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectBloodBlood - brain barrier anatomyBlood PlateletsBrainBrain InjuriesBrain IschemiaCause of DeathCell DeathCell membraneCerebrovascular CirculationCerebrumCleaved cellClinicalClinical TrialsCognitiveContusionsDevelopmentDisintegrinsDoseEndothelial CellsEndotheliumEnvironmentEventExperimental ModelsExtravasationFemaleGoalsHeart failureHourHumanImaging technologyInjuryIntravenousIschemiaLaser Scanning Confocal MicroscopyLeadMagnetic Resonance ImagingMeasuresMechanicsMediatingMembraneMetalloproteasesMindMuscular DystrophiesNerve DegenerationNeurological outcomeOutcomePatientsPerfusionPermeabilityPharmaceutical PreparationsPlasmaPlatelet ActivationPlatelet aggregationPoloxamer 188PolyethylenesPolypropylenesQuality of lifeRattusRecovery of FunctionReportingResearchSecondary toSensorimotor functionsTestingTherapeuticTherapeutic EffectThrombosisThrombospondinsTissuesToxic effectTraumatic Brain InjuryTraumatic Brain Injury recoveryTreatment EfficacyUrsidae FamilyWorkamphiphilicitycell injurycontrolled cortical impactcopolymerdisabilityeffective therapyelectrical injuryimprovedin vivoinjuredintravenous administrationkidney dysfunctionmalemortalityneuroinflammationneurological recoveryneuron lossneuroprotectionneurorestorationnovel strategiesnovel therapeutic interventionnovel therapeuticspreclinical trialpreservationpreventrelease factorsealtherapy designtreatment strategyvon Willebrand Factor
项目摘要
PROJECT SUMMARY/ABSTRACT
Traumatic brain injury (TBI) is a major cause of death and disability worldwide. There are no effective therapies
available for TBI patients. Thus, there is a compelling need to develop novel therapeutics in order to improve
neurological recovery after TBI. Among many secondary injury events that occur after TBI, cerebral
microthrombosis is an under-recognized, yet important contributor to the secondary brain ischemia and damage
that occurs after TBI, and would therefore seem to be one of the central secondary events after brain trauma to
bear in mind when designing treatment strategies. Cerebral microthrombi not only lead to ischemia and cell
death but also prevent therapeutic drugs from entering into the affected brain and therefore constrain the
efficacy of therapeutic drugs, which may be one of important factors ignored during preclinical and clinical trials.
Our recent study indicates that early (2 hours post injury) intravenous administration of Vepoloxamer promotes
sensorimotor function and cognitive functional recovery after TBI induced by controlled cortical impact
(CCI-TBI), which is associated with its robust effect on reducing cerebral microthrombosis formation and
neuroinflammation. Vepoloxamer is a purified form of Poloxamer 188 where impurities associated with renal
dysfunction have been removed, which is an amphiphilic polyethylene-polypropylene-polyethylene tri-block
copolymer that is reported to seal membranes and restore plasma membrane integrity in damaged cells.
However, to date, there is a paucity of information about Vepoloxamer for treatment of TBI and the mechanisms
underlying its therapeutic effects. von Willebrand factor (vWF) released into blood from injured endothelial cells
inversely correlates with clinical outcome of severe TBI. vWF can induce microthrombosis formation. Our
previous study demonstrated that the level of vWF released into plasma increases at 1-4 hours, peaks at 1-3
days, declines at 8 days, and returns to normal at 15 days in rats after CCI-TBI. We hypothesize that TBI
induces the blood-brain barrier (BBB) damage and release of endothelial-derived vWF, which leads to platelet
aggregate and subsequent cerebral microthrombosis-induced secondary injury. In Aim 1, we will first conduct a
dose-finding study to identify Vepoloxamer dose and therapeutic window effect on functional recovery without
toxicity in young rats (male and female) with TBI. In Aim 2, we will then investigate the mechanisms by which IV
administration of Vepoloxamer enhances cerebral microvascular perfusion and promotes functional recovery
after TBI. Microvascular integrity, cerebral blood flow, and BBB leakage will be measured dynamically using
either laser scanning confocal microscopy or magnetic resonance imaging (MRI). This work will address a
previously understudied important issue and is highly translational. Successful completion of this proposed
research will elucidate mechanisms underlying IV Vepoloxamer-mediated promotion of TBI recovery, and
facilitate development of Vepoloxamer as a novel therapeutic approach targeting endothelial cells/microthrombi
to improve neurological outcome for TBI patients.
项目总结/摘要
创伤性脑损伤(TBI)是世界范围内死亡和残疾的主要原因。没有有效的治疗方法
可用于TBI患者。因此,迫切需要开发新的治疗剂,以改善患者的免疫功能。
TBI后的神经恢复在TBI后发生的许多继发性损伤事件中,脑损伤是最常见的。
微血栓形成是继发性脑缺血和脑损伤的重要因素,
这发生在TBI之后,因此似乎是脑外伤后的中心继发事件之一,
在设计治疗策略时要牢记。脑微血栓不仅导致缺血和细胞凋亡,
死亡,但也阻止治疗药物进入受影响的大脑,因此限制了
治疗药物的有效性,这可能是临床前和临床试验中被忽视的重要因素之一。
我们最近的研究表明,早期(损伤后2小时)静脉注射维泊洛沙姆可促进
控制性皮质撞击诱导脑外伤后感觉运动功能和认知功能恢复
(CCI-TBI),这与其减少脑微血栓形成的强大作用有关,
神经炎症维泊洛沙姆是泊洛沙姆188的纯化形式,其中杂质与肾脏相关
功能障碍已被删除,这是一个两亲性聚乙烯-聚丙烯-聚乙烯三嵌段
据报道,该共聚物可密封膜并恢复受损细胞中的质膜完整性。
然而,到目前为止,关于维泊洛沙姆治疗TBI及其机制的信息还很少。
其治疗效果的基础。血管性血友病因子(vWF)从受损的内皮细胞释放到血液中
与严重TBI的临床结果呈负相关。vWF可诱导微血栓形成。我们
先前的研究表明,释放到血浆中的vWF水平在1-4小时增加,在1-3小时达到峰值,
在CCI-TBI大鼠中,在第8天下降,并且在第15天恢复正常。我们假设创伤性脑损伤
诱导血脑屏障(BBB)损伤和内皮源性vWF的释放,这导致血小板聚集。
聚集和随后的脑微血栓形成引起的继发性损伤。在目标1中,我们将首先进行
剂量探索研究,以确定维泊洛沙姆剂量和治疗窗对功能恢复的影响,
TBI幼鼠(雄性和雌性)的毒性。在目标2中,我们将研究IV
给予维泊洛沙姆增强脑微血管灌注并促进功能恢复
脑外伤后。微血管完整性、脑血流量和BBB渗漏将使用
激光扫描共聚焦显微镜或磁共振成像(MRI)。这项工作将解决
以前未充分研究的重要问题,是高度翻译。圆满完成本次拟
研究将阐明IV维泊洛沙姆介导的促进TBI恢复的潜在机制,
促进Vepoloxamer作为靶向内皮细胞/微血栓的新型治疗方法的开发
以改善TBI患者的神经功能结局。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yanlu Zhang其他文献
Yanlu Zhang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yanlu Zhang', 18)}}的其他基金
Treatment of traumatic brain injury with vepoloxamer
维泊洛沙姆治疗颅脑损伤
- 批准号:
10418779 - 财政年份:2019
- 资助金额:
$ 32.92万 - 项目类别:
Treatment of traumatic brain injury with vepoloxamer
维泊洛沙姆治疗颅脑损伤
- 批准号:
10621791 - 财政年份:2019
- 资助金额:
$ 32.92万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 32.92万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 32.92万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 32.92万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 32.92万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 32.92万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 32.92万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 32.92万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 32.92万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 32.92万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 32.92万 - 项目类别:
Grant-in-Aid for Early-Career Scientists